- Home
- FLC vs CRVS Comparison
FLC vs CRVS Comparison
Compare FLC & CRVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | FLC | CRVS |
|---|---|---|
| Founded | 2003 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 181.5M | 546.7M |
| IPO Year | N/A | 2016 |
Fundamental Metrics
Financial Performance| Metric | FLC | CRVS |
|---|---|---|
| Price | $17.42 | $6.61 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $13.75 |
| AVG Volume (30 Days) | 37.8K | ★ 1.7M |
| Earning Date | 01-01-0001 | 11-04-2025 |
| Dividend Yield | ★ 6.64% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $12.62 | $2.54 |
| 52 Week High | $15.45 | $9.60 |
Technical Indicators
Market Signals| Indicator | FLC | CRVS |
|---|---|---|
| Relative Strength Index (RSI) | 49.35 | 31.62 |
| Support Level | $17.44 | $7.28 |
| Resistance Level | $17.60 | $7.81 |
| Average True Range (ATR) | 0.16 | 0.46 |
| MACD | 0.01 | -0.12 |
| Stochastic Oscillator | 39.47 | 9.54 |
Price Performance
Historical ComparisonAbout FLC Flaherty & Crumrine Total Return Fund Inc
Flaherty & Crumrine Total Return Fund Inc is a diversified, closed-end investment management company. Its investment objective is to provide its common shareholders with a high current income. The fund's secondary investment objective is capital appreciation.
About CRVS Corvus Pharmaceuticals Inc.
Corvus Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing product candidates that precisely target proteins that are critical to immune cell maturation and function. Its product candidate, soquelitinib, is designed to bind specifically to a protein, interleukin 2 inducible T cell kinase (ITK), involved in T cell activation, T cell receptor signaling and T cell differentiation and function. The other products include Ciforadenant (CPI-444) and Mupadolimab (CPI-006).